Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2006 Oct;77(10):1116-21.
doi: 10.1136/jnnp.2005.086074. Epub 2006 Jul 4.

A randomised pilot study to assess the efficacy of an interactive, multimedia tool of cognitive stimulation in Alzheimer's disease

Affiliations
Randomized Controlled Trial

A randomised pilot study to assess the efficacy of an interactive, multimedia tool of cognitive stimulation in Alzheimer's disease

L Tárraga et al. J Neurol Neurosurg Psychiatry. 2006 Oct.

Abstract

Objective: To determine the usefulness of an interactive multimedia internet-based system (IMIS) for the cognitive stimulation of Alzheimer's disease.

Methods: This is a 24-week, single-blind, randomised pilot study conducted on 46 mildly impaired patients suspected of having Alzheimer's disease receiving stable treatment with cholinesterase inhibitors (ChEIs). The patients were divided into three groups: (1) those who received 3 weekly, 20-min sessions of IMIS in addition to 8 h/day of an integrated psychostimulation program (IPP); (2) those who received only IPP sessions; and (3) those who received only ChEI treatment. The primary outcome measure was the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog). Secondary outcome measures were: Mini-Mental State Examination (MMSE), Syndrom Kurztest, Boston Naming Test, Verbal Fluency, and the Rivermead Behavioral Memory Test story recall subtest.

Results: After 12 weeks, the patients treated with both IMIS and IPP had improved outcome scores on the ADAS-Cog and MMSE, which was maintained through 24 weeks of follow-up. The patients treated with IPP alone had better outcome than those treated with ChEIs alone, but the effects were attenuated after 24 weeks. All patients had improved scores in all of the IMIS individual tasks, attaining higher levels of difficulty in all cases.

Conclusion: Although both the IPP and IMIS improved cognition in patients with Alzheimer's disease, the IMIS program provided an improvement above and beyond that seen with IPP alone, which lasted for 24 weeks.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Similar articles

Cited by

References

    1. Ott A, Breteler M M, van Karskamp F.et al Incidence and risk of dementia. The Rotterdam Study. Am J Epidemiol 1998147574–580. - PubMed
    1. Fratiglioni L, Launer L J, KA, Breteler M M.et al Incidence of dementia and major subtypes in Europe: a collaborative study of population‐based cohorts. Neurology 200054S10–S15. - PubMed
    1. Rogers S L, Friedhoff L T. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double‐blind, placebo‐controlled trial. The Donepezil Study Group. Dementia 19967293–303. - PubMed
    1. Rosler M, Anand R, Cicin‐Sain A.et al Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999318633–638. - PMC - PubMed
    1. Raskind M A, Peskind E R, Wessel T.et al Galantamine in AD. A six‐month, randomized, placebo‐controlled trial with a six‐month extension. Neurology 2000542261–2268. - PubMed

Publication types